UK universities and GSK expand collaboration

Manjula Puthenedam, PhD, | | Health Imaging | Molecular Imaging
The Medical Research Council in London, Imperial College London, King’s College London and University College London have become equal shareholders in a newly created joint venture with GlaxoSmithKline’s Clinical Imaging Center.

The 47 million GBP ($76.7 million USD) center on Imperial College London’s Hammersmith Hospital campus has carried out GlaxoSmithKline-dedicated research in close collaboration with academic researchers since it opened in 2007, according to the company.

Under the new arrangements, the research and technical expertise of the four partners will help to drive the center into new areas and applications of imaging. The center's operations and staff are expected to transfer to the newly formed joint venture in the third quarter of the year, added the company.

Manjula Puthenedam, PhD,

Related Content

Dementia cases are about to skyrocket—how will this affect imaging demand?
Experts update AUC for amyloid, tau PET imaging for first time in more than a decade
Repurposed radiotracer lights up treatment-resistant tumors 'like a Christmas tree'
Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.